Menu Close

Johnson & Johnson (NYSE:JNJ) Shares Sold by Harel Insurance Investments & Financial Services Ltd.

view original post

Harel Insurance Investments & Financial Services Ltd. trimmed its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 36.0% during the first quarter, HoldingsChannel.com reports. The firm owned 28,850 shares of the company’s stock after selling 16,240 shares during the period. Harel Insurance Investments & Financial Services Ltd.’s holdings in Johnson & Johnson were worth $5,113,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the business. Vantage Financial Partners Ltd. Inc. raised its position in shares of Johnson & Johnson by 1.4% during the 1st quarter. Vantage Financial Partners Ltd. Inc. now owns 14,705 shares of the company’s stock valued at $2,606,000 after acquiring an additional 200 shares in the last quarter. Hallmark Capital Management Inc. raised its position in shares of Johnson & Johnson by 2.6% during the 1st quarter. Hallmark Capital Management Inc. now owns 129,589 shares of the company’s stock valued at $22,967,000 after acquiring an additional 3,299 shares in the last quarter. Truvestments Capital LLC raised its position in shares of Johnson & Johnson by 1.6% during the 1st quarter. Truvestments Capital LLC now owns 19,391 shares of the company’s stock valued at $3,437,000 after acquiring an additional 306 shares in the last quarter. Paulson Wealth Management Inc. raised its position in shares of Johnson & Johnson by 2.1% during the 1st quarter. Paulson Wealth Management Inc. now owns 6,173 shares of the company’s stock valued at $1,094,000 after acquiring an additional 127 shares in the last quarter. Finally, Congress Park Capital LLC raised its position in shares of Johnson & Johnson by 0.8% during the 1st quarter. Congress Park Capital LLC now owns 9,341 shares of the company’s stock valued at $1,656,000 after acquiring an additional 75 shares in the last quarter. 68.78% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on JNJ shares. SVB Leerink lowered their price objective on Johnson & Johnson from $200.00 to $194.00 in a research note on Wednesday, July 20th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 17th. Citigroup lowered their price objective on Johnson & Johnson from $205.00 to $201.00 in a research note on Wednesday, July 20th. The Goldman Sachs Group upped their price objective on Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a research note on Tuesday, April 12th. Finally, Credit Suisse Group upped their price objective on Johnson & Johnson from $200.00 to $205.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 20th. Four analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $189.89.

Johnson & Johnson Trading Up 0.2 %

Shares of JNJ stock opened at $174.52 on Friday. The stock has a 50-day simple moving average of $175.95 and a 200 day simple moving average of $174.42. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The stock has a market capitalization of $459.23 billion, a P/E ratio of 25.40, a P/E/G ratio of 3.28 and a beta of 0.63. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt-to-equity ratio of 0.39.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.56% and a net margin of 19.21%. The business had revenue of $24.02 billion during the quarter, compared to analysts’ expectations of $23.85 billion. During the same quarter last year, the business posted $2.48 earnings per share. The company’s quarterly revenue was up 3.0% on a year-over-year basis. On average, sell-side analysts expect that Johnson & Johnson will post 10.05 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be paid a dividend of $1.13 per share. The ex-dividend date is Monday, August 22nd. This represents a $4.52 annualized dividend and a yield of 2.59%. Johnson & Johnson’s dividend payout ratio is currently 65.79%.

Insider Activity

In other news, CAO Robert J. Decker sold 8,462 shares of the company’s stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the sale, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at $2,785,140. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction on Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the sale, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at $12,336,803. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Robert J. Decker sold 8,462 shares of the company’s stock in a transaction on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the sale, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at $2,785,140. The disclosure for this sale can be found here. 0.35% of the stock is currently owned by company insiders.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.